Global Partners LP

GLP | NYSE

Price Alert Chart Builder DCF Calculator

$50.62

+$1.64 (+3.35%)

At close: Sep 21, 2026, 4:00 PM ET

$51.08

+$0.46 (+0.91%)

After-hours: Sep 21, 2026, 5:58 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Dividends Profile

+3.35%

(1D)

Rating

Updated: Sep 5, 2026

50.1

Fundamentals Average

Market Sentiment Bullish

Moat Narrow

Full Analysis

Key Statistics

Market Data

Market Cap $1.72B

1D Range

48.96 50.63

52W Range

39.58 54.29

Valuation (TTM)

PE 10.33

PB 2.30

EV/EBITDA 13.30

Valuation (NTM)

Forward PE 12.80

Forward PEG -0.28

Price Target $46

Cash Flow

FCF Yield 15.0%

SBC Adj. FCF Yield 14.8%

SBC Impact -1.3%

Margins

Gross Margin 5.9%

Operating Margin 2.5%

FCF Margin 1.2%

Growth (CAGR)

Revenue 3Y | 5Y 8.3% | 16.3%

Dil EPS 3Y | 5Y -8.6% | 43.0%

FCF 3Y | 5Y 3.7% | -36.2%

Returns

ROA 4.3%

ROE 24.6%

ROIC 17.5%

Financial Health

Net Debt

$1.58B

Current Ratio 1.19

Interest Coverage 8.37

Dividends

Div Yield 6.05%

Payout Ratio 62.5%

FCF Payout Ratio 37.4%

All Key Statistics

Loading financial charts...

Profile

Global Partners LP engages in the purchasing, selling, gathering, blending, storing, and logistics of transporting gasoline and gasoline blendstocks, distillates, residual oil, renewable fuels, crude ...

Sector Energy

Industry Oil & Gas Midstream

Employees 4,700

IPO Date Oct 3, 2005

Website www.globalp.com

Fiscal Year January - December

Full Company Profile

Latest News

19 hours ago · cnbc.com

Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs

Eli Lilly CEO Dave Ricks told CNBC on Monday that 700,000 new seniors have started GLP-1 treatments since Medicare coverage of obesity drugs launched in July. In an exclusive interview, Ricks said 70% of those patients are on Lilly medicines.

20 hours ago · cnbc.com

Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production

1 day ago · marketbeat.com

WW International Eyes Cash Flow Turnaround as GLP-1 Care Gains Momentum

WW International NASDAQ: WW executives outlined the company's efforts to reposition its weight-management business around behavioral support, telehealth and GLP-1 medications, following a restructuring that substantially reduced its debt burden.

3 days ago · youtube.com

40% of U.S. Adults to Use GLP-1s? Raul Shah on LLY, NVO & Weight Loss "Mania"

Raul Shah (@Raul_DSF) is very bullish on the future of GLP-1s due to accelerating demand trends generating a "mania" effect in the market. He points to the superiority Eli Lilly (LLY) has demonstrated through earnings and weighs if Novo (NVO) has a chance to catch up.

4 days ago · seekingalpha.com

Kailera Therapeutics: An Outside Biotech Bet For The Next GLP-1 Obesity Drug Approval

Kailera Therapeutics, Inc. targets the high-potential GLP-1 obesity market, leveraging a $718M IPO and a robust pipeline licensed from Hengrui. KLRA's lead candidate, ribupatide, shows competitive mean weight loss (23.6% at 36 weeks) and a favorable safety profile in ex-China studies. Despite a 40% post-IPO share price drop, KLRA's $1.65 bn valuation appears attractive given its late-stage pipeline and $900m cash balance.

5 days ago · fool.com

Where Will Novo Nordisk Be in 5 Years as the GLP-1 Market Gets More Crowded?

Novo Nordisk has lost its lead in the weight loss market. The company could face even more competition going forward.

6 days ago · zacks.com

Are Investors Undervaluing Global Partners (GLP) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

7 days ago · accessnewswire.com

The GLP-1 Era Has a Trust Problem - AimwellBio is Building the Physician Network to Solve It

Company plans to integrate telemedicine into its verified health intelligence platform and opens a ten-seat Founding Physician Cohort spanning GLP-1 and metabolic care, hormone and menopause health, and physician-directed therapies for men and women. MIAMI, FL / ACCESS Newswire / September 15, 2026 / Aimwell Partners Inc. (OTCID:AIMN), parent company of AimwellBio, today announced plans to integrate telemedicine capabilities into its verified health intelligence platform and opened applications for its Founding Physician Cohort.

11 days ago · youtube.com

Making Getting Skinny Taste Good: Cava CEO On The GLP-1 Boom

From smaller portions and adults ordering kids meals to more protein and Mediterranean-style eating, Cava CEO Brett Schulman breaks down how GLP-1s are changing customer behavior. Check out our daily newsletter!